Xenetic Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
XBIO Nasdaq 2836 www.xeneticbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting - Dec 11th, 2025 3:00 pm
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform - Nov 19th, 2025 6:45 am
Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results - Nov 13th, 2025 6:45 am
Xenetic Biosciences: Q3 Earnings Snapshot - Nov 12th, 2025 3:43 pm
Amneal Pharmaceuticals (AMRX) Beats Q3 Earnings and Revenue Estimates - Oct 30th, 2025 5:15 am
Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock - Oct 10th, 2025 7:30 am
Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results - Aug 13th, 2025 6:00 am
Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates - Aug 12th, 2025 4:25 pm
Xenetic Biosciences: Q2 Earnings Snapshot - Aug 12th, 2025 3:26 pm
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma - Jul 30th, 2025 7:00 am
Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform - Jul 23rd, 2025 6:30 am
Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic Cancer - Jul 8th, 2025 7:00 am
Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update - May 14th, 2025 6:05 am
Xenetic Biosciences: Q1 Earnings Snapshot - May 13th, 2025 3:10 pm
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment - Apr 9th, 2025 7:15 am
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma - Mar 26th, 2025 7:00 am
Xenetic Biosciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Mar 20th, 2025 5:00 am
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results - Mar 19th, 2025 6:05 am
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses - Mar 13th, 2025 6:30 am
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting - Feb 27th, 2025 7:15 am